---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

FORM 8-K

 

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 28, 2006

Date of Report (Date of earliest event reported)

 

---

ANTIGENICS INC.

(Exact name of registrant as specified in its charter)

 

---

 

DELAWARE		000-29089		06-1562417
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

630 Fifth Avenue, Suite 2100
New York, NY 10111		10111
(Address of principal executive offices)		(Zip Code)

212-994-8200

(Registrant’s telephone number, including area code)

 

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

---

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Mark Kessel and Alastair Wood each has informed Antigenics that he intends to resign from the Antigenics Board of Directors on September 14, 2006.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		ANTIGENICS INC.
Date: September 1, 2006
		By:		/s/ Peter Thornton
				Peter Thornton
				Senior Vice President and Chief Financial Officer